Pfizer delays patent cliff for blockbuster Vyndamax

April 28, 2026 01:36 PM EDTUpdated 03:22 PM PharmaMarketingLaw Pfiz­er de­lays patent cliff for block­buster heart drug Nicole DeFeudis Senior Reporter Pfiz­er is staving off Vyn­damax com­pe­ti­tion for an­oth­er two years. The drug, al­so known as tafamidis, is among Pfiz­er’s top three Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER